Chelsea Therapeutics $658M Merger 'Unfair,' Investors Say
Chelsea Therapeutics International Ltd. was slapped with a putative stockholder class action Friday in Delaware Chancery Court alleging its proposed $658 million merger with Denmark's H. Lundbeck A/S undervalues the company....To view the full article, register now.
Already a subscriber? Click here to view full article